An Ancient Genetic Twist and Its Modern Impact on Brain Disease
More than two million years ago, a segment of DNA flipped orientation in the human genome.
In this first-person account, Cathrine Sant, PhD, shares her journey from studying statistics and neurobiology to investigating one of the most intriguing regions of the human genome. She describes how the NOMIS–Gladstone Fellowship is helping her explore the health impact of this region, known as the MAPT locus, and uncover how an ancient genetic inversion at this site may influence the risk of Alzheimer’s disease and other neurodegenerative disorders today.
The NOMIS–Gladstone Fellowship supports innovative, interdisciplinary research that empowers early-career scientists to pursue ambitious questions and establish independent research programs.
Bridging Computational Biology and Neuroscience
A small stretch of DNA flipped orientation in a subset of our ancestors 2.3 million years ago. This ancient inversion in our genome may help explain why some people are more vulnerable to Alzheimer’s disease and other neurodegenerative disorders today.
I was born in Denmark and grew up largely in California, where I first became interested in the intersection of computation and biology. As an undergraduate studying statistics and neurobiology at the University of California, Berkeley, I joined a neuropathology lab across the bay at the University of California, San Francisco. There, I was introduced to the gene at the center of this curious region of the human genome: MAPT. Tau, the protein encoded by MAPT, is a defining feature of Alzheimer’s disease and related disorders known as tauopathies.
My increasing interest in the underlying causes of these diseases led me to pursue a doctorate in neuroscience at UCSF. During my graduate training, I realized how computational approaches could be harnessed to effectively leverage the power of large-scale datasets to reveal changes in the expression of thousands of genes. I therefore developed CHOIR, an algorithm designed to identify biologically distinct cell types from such datasets, which has since enabled us to examine the therapeutic potential of lowering tau levels in specific brain cell types.
Investigating a Genomic Mystery
As a NOMIS–Gladstone Fellow co-advised by Ryan Corces, PhD, and Lennart Mucke, MD, I am now focusing on the complex genetic landscape around MAPT. The two inverted forms, or haplotypes, of this region have acquired different properties during evolution, and, intriguingly, are associated with substantially different risks for several neurodegenerative diseases.
Connecting Evolution, Genetics, and Disease
It remains unclear how this single genomic region controls risk for a variety of diseases. I am investigating whether distinct mechanisms of gene regulation and splicing across specific brain cell types may be responsible for the differences in disease risk.
By dissecting the functional impact of this locus, I hope to better understand both the biology of tauopathies and the broader evolutionary dynamics that have sculpted complex regions of the human genome that affect higher cognition and many other important brain functions.
The NOMIS-Gladstone Fellowship Program gives me the intellectual freedom and mentorship to pursue these and other foundational questions that could shape the way we treat neurodegenerative disorders in the future.
Up Next
Gladstone Institutes Announces Andrew S. Garb’s Transition to Emeritus Trustee
After more than four decades of dedicated legal and governance leadership, including 22 years as a trustee, Garb will transition to emeritus status in 2027.
Study Rewrites the Rules of the Blood-Brain Barrier
Gladstone scientists discover the dynamic barrier—long defined by what it excludes—imports an unexpected degree of protective proteins into the brain, revealing a new blueprint for treating Alzheimer’s disease.
How AI Is Filling the Gaps in Women’s Health Research
A Gladstone-led study is collecting data from thousands of women wearing Oura Rings to make sense of what’s normal—and what could signal problems—when it comes to the menstrual cycle.
Christina Theodoris to Receive ASCI’s 2026 Seldin-Smith Award for Pioneering Research
The prestigious honor is presented by the American Society for Clinical Investigation to a physician-scientist making transformative contributions to biomedical research.
Get Involved
Join the Team
Our people are our most important asset. We offer a wide array of career opportunities both in our administrative offices and in our labs.
Open PositionsPartner With Us
Discoveries don’t stay in our labs. Gladstone facilitates spinout companies to advance promising therapies, shortening the path between scientific discovery and helping real patients.
Learn MoreGive
Your gift to Gladstone will allow our researchers to pursue high-quality science, focus on disease, and train the next generation of scientific thought leaders.
Donate Now